Refractory Hematologic Malignancies Or Solid Tumors clinical trials

Explore recruiting refractory hematologic malignancies or solid tumors clinical trials.

Recruiting refractory hematologic malignancies or solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Hematologic Malignancies Or Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Actuate 1801: Phase 1/2 Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Portugal, Belgium, France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Refractory Hematologic Malignancies Or Solid Tumors trials by city

Refractory Hematologic Malignancies Or Solid Tumors in Toronto Refractory Hematologic Malignancies Or Solid Tumors in Vancouver Refractory Hematologic Malignancies Or Solid Tumors in Montreal Refractory Hematologic Malignancies Or Solid Tumors in Calgary Refractory Hematologic Malignancies Or Solid Tumors in Edmonton Refractory Hematologic Malignancies Or Solid Tumors in Ottawa Refractory Hematologic Malignancies Or Solid Tumors in Winnipeg Refractory Hematologic Malignancies Or Solid Tumors in Quebec City Refractory Hematologic Malignancies Or Solid Tumors in Hamilton Refractory Hematologic Malignancies Or Solid Tumors in Kitchener Refractory Hematologic Malignancies Or Solid Tumors in London Refractory Hematologic Malignancies Or Solid Tumors in Halifax Refractory Hematologic Malignancies Or Solid Tumors in New York Refractory Hematologic Malignancies Or Solid Tumors in Los Angeles Refractory Hematologic Malignancies Or Solid Tumors in Chicago Refractory Hematologic Malignancies Or Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease